Some on this board like cling to the way-back machine. Lonza's been out of the picture for years.

Of course, they made that all up. I mean, it isn't like Cytodyn has been under the FDA microscope for 2 years. Sure, they can just say whatever they want, much like you. No problem.

AGC was manufacturing leronlimab before Samsung, remember?

A post from Jake2212 on another board.....
"CYDY's recent transfer of LL manufacturing technology, without identifying the recipient, and under circumstances where a drug manufacturing competitor of Samsung would be unlikely to extend credit to CYDY, leaves only drug companies with in house manufacturing capabilities as viable recipients of the technology -- and that type of a transfer can only mean BO or partnership, cloaked for the time being in a NDA."

A technology transfer has been COMPLETED to a manufacturer. This is a one year process, so it's been in the works for some time. Secondly, Samsung is now out of the picture as a manufacturer, leaving only AGC and the new, unknown entity. Read the tea leaves.

Bahaha....the technology transfer to another lab has been completed. A partner, or perhaps a buyer?

No more Vyera, but unfortunately another company assumed the agreement.....
https://www.biospace.com/article/releases/regnum-signs-assignment-and-assumption-agreement-with-cytodyn-and-sevenscore-pharmaceuticals-to-commercialize-leronlimab-in-the-u-s-for-the-treatment-of-hiv/

Here's an older study of MS patients which indicated a slower disease progression in the CCR5 deleted population.

https://www.hindawi.com/journals/msi/2011/153282/

P=.0001

Perhaps this is that which you seek:
https://www.researchgate.net/profile/Neil-Buss

https://www.researchgate.net/profile/Neil-Buss

What milestones are those? You apparently don't know, either. Refer to your Post #218685.

There is also extended mTNBC survival data looming for a second attempt at a BTD.

And yet here we are, with Citigroup coverage of CYDY initiated.

True that!

Did you ever consider that CitiGroup knows one hell of a lot more than you about CytoDyn and what's going on behind the curtain?

Has anyone considered what LL approval will mean to countries with single-payer health systems, ie. UK, Canada, Japan, and virtually every other advanced nation on the planet? BOOM...the agencies will be on LL like flies on ape^$@*! One drug which addresses multiple indications will change medicine and provide health agenies a huge monitary benefit by moving them from under the thumb of big pharma and all the middle-men taking their cut.
IMO

Nader does not design trials. Trials are agree upon between FDA, CRO and the company, but mainly the FDA calls the shots. Why are you so insistant that Nader has anything to do with the final configuration of a trial? Newsflash....he doesn't.

It's great to have a shiny, new thing to toss at the impatient morons, but, as the old saying goes, you can't polish a turd. The'Ders want you to believe they will actually use this plan. That's not in the cards. What is in that deck of cards is a systematic dismantle of CytoDyn, a great sucking sound, and sale of LL to the highest bidder. Of course, this won't take place until the current investors are ruined financially through dilutions and reverse splits. The 'Ders will 'haz all the cheesebugers' by then. Don't let that happen.

The litigation expense really isn't for 'naught'. It reduced the 7%ers downto <1%ers.

It has little to do with the expense. This is a tiny biotech trying to juggle about 30 indications for it's molecule and it simply doesn't have the time or resources to wade through the rediculous amout of paperwork required for EIND or 'Right to Try'. But of course you knew that, right?

It's highly doubtful any management team is perfect, but the CYDY team meshes well and all the oars are pulling the canoe in the same direction. With a 13D takeover I see a huge potential for flaring egos and complete paralysis pertaining to advancing Leronlimab for any indication. This is exactly what big pharma/FDA wants and why many on this board are constantly bashing. They all have some vested interest in halting advancement of this molecule, or they wouldn't be doing what they're doing.
IMO

The FDA seems to excel at fatal decisions of late.

That's fantastic news, misiu! I hope the LL comes in time to help your son. Prayers to you and your family.

It's an aggregate of unreported trades for the day. Nothing more sinister than that.

"Chiral Pharma Corporation in the Philippines placed its first purchase order for leronlimab" - (A 'purchase order' is the contract drafted by the buyer when purchasing goods from the seller, remember from our previous lesson?)

I copied the simple definition for you.

"What is purchase order in simple words?
A purchase order is a commercial source document. ... The document indicates the details on the items that are to be purchased, such as the types of goods, quantity, and price. In simple terms, it is the contract drafted by the buyer when purchasing goods from the seller."

Barcitinib and remdeathisnear are both bad jokes on the world. India finally got the balls to shitcan both. The US FDA has led the country and the world down a path with no hope. So much for the 'gold standard'. LL to the rescue....4 doses.

Apparently you haven't noticed that the Phillipine people use nick names a lot. Richard - Randy, same person....big deal.
He also owns shares of CytoDyn. Again, big deal. Anyone who has studied the science behind this molecule and has at least one funtioning brain cell has also purchased shares.

There are 7 Gilead affiliated board members on the NIH COVID-19 Treatment Guidelines Advisory Board. Big Pharma supplies the FDA with about 75% of it's drug review budget.
https://www.covid19treatmentguidelines.nih.gov/panel-financial-disclosure/
https://www.forbes.com/sites/johnlamattina/2018/06/28/the-biopharmaceutical-industry-provides-75-of-the-fdas-drug-review-budget-is-this-a-problem/

The Serum Institute of India is the world's largest vaccine manufacturer and produces almost 100 millions doses of AstraZeneca Covid-19 vaccine per month.

"I drink, and I know things'....Tyrion Lannister.

If this thing actually goes to Court, there will be several butt-hurt lawyers after the judge tears them a new one for wasting the court's time. This 300 share plantiff is down about $12.90. LOL

"Recently, the FDA granted Compassionate Special Permits (CSP) for Leronlimab as requested by medical specialists for the treatment of COVID-19 patients."

$60/sh buyout with 2>1 share exchange....2 CYDY to 1 BP. Looking at you, Johnson and Johnson.

It's also true.

Thank you, misiu.

It's interesting you should bring up a GM-CSF mediator, like Lenzulimab, in this forum. You do know that CCR5 controls much of the downstream biology including GM-CSF, don't you? Leromlimab > Lenzulimab.

And how much does Dr. Marc Siegel have invested in Merck and Ridgeback Biotherapeutics?

Nice summary and response, CT.